Angiogenesis

During her talk at Angiogenesis, Dr. Loewenstein outlines how artificial intelligence could revolutionize diabetic retinopathy screening.

After 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.

Jay S. Duker, MD, who presented data at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, noted that previously treated patients showed a significantly reduced treatment

At Angiogenesis, Dr. SriniVas R. Sadda discusses how choriocapillaris may predict the rate of progression of atrophy.

During a presentation at the Bascom Palmer Eye Institute's Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition conference, David S. Boyer, MD, explained that the drug, which is being considered to treat diabetic retinopathy, renal disease, and age-related macular degeneration, is intended to be an alternative therapy to monthly chronically administered intravitreal injections of anti-VEGF drugs.

In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.

Dr. Nadia K. Waheed reviews the latest updates on the FOCUS trial, evaluating AAV-based viral vector GT005 for the treatment of geographic atrophy.

In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Amir Kashani, MD, PhD, discussed results that show the implant procedure is feasible on an outpatient basis and has a good safety and efficacy profile.

Dr. David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.

This Bascom Palmer Eye Institute 2-day virtual scientific program promises a distinguished international faculty who will share the latest developments in imaging, translational research, and clinical trials as well as the impact these advances will have on clinical ophthalmology.